Magnetic Resonance Imaging Investigation of Secondary Degeneration of the Mesencephalic Substantia Nigra After Cerebral Infarction

Author(s):  
Yasuko Ohe ◽  
Akira Uchino ◽  
Yousuke Horiuchi ◽  
Hajime Maruyama ◽  
Ichiro Deguchi ◽  
...  
Author(s):  
Lu Wang ◽  
Yayun Yan ◽  
Liyao Zhang ◽  
Yan Liu ◽  
Ruirui Luo ◽  
...  

AbstractNeuromelanin (NM) is a dark pigment that mainly exists in neurons of the substantia nigra pars compacta (SNc). In Parkinson disease (PD) patients, NM concentration decreases gradually with degeneration and necrosis of dopamine neurons, suggesting potential use as a PD biomarker. We aimed to evaluate associations between NM concentration in in vivo SN and PD progression and different motor subtypes using NM magnetic resonance imaging (NM-MRI). Fifty-four patients with idiopathic PD were enrolled. Patients were divided into groups by subtypes with different clinical symptoms: tremor dominant (TD) group and postural instability and gait difficulty (PIGD) group. Fifteen healthy age-matched volunteers were enrolled as controls. All subjects underwent clinical assessment and NM-MRI examination. PD patients showed significantly decreased contrast-to-noise ratio (CNR) values in medial and lateral SN (P < 0.05) compared to controls. CNR values in lateral SN region decreased linearly with PD progression (P = 0.001). PIGD patients showed significant decreases in CNR mean values in lateral SN compared to TD patients (P = 0.004). Diagnostic accuracy of using lateral substantia nigra (SN) in TD and PIGD groups was 79% (sensitivity 76.5%, specificity 78.6%). NM concentration in PD patients decreases gradually during disease progression and differs significantly between PD subtypes. NM may be a reliable biomarker for PD severity and subtype identification.


2018 ◽  
Vol 11 ◽  
pp. 175628641875949 ◽  
Author(s):  
Jonathon P. Fanning ◽  
Louise E. See Hoe ◽  
Margaret R. Passmore ◽  
Adrian G. Barnett ◽  
Barbara E. Rolfe ◽  
...  

1987 ◽  
Vol 29 (5) ◽  
pp. 422-429 ◽  
Author(s):  
S. Imakita ◽  
T. Nishimura ◽  
H. Naito ◽  
N. Yamada ◽  
K. Yamamoto ◽  
...  

Author(s):  
S Luo ◽  
X Wu ◽  
F Deng ◽  
Y Zhang ◽  
J Miao ◽  
...  

Background: Assessment of ischemic penumbra during the acute stage of cerebral infarction is crucial for a decision to initiate thrombolytic therapy and for predicting stroke evolution. Although controversial as a perfect equivalence to penumbra, perfusion weighted imaging (PWI)-diffusion weighted imaging (DWI) mismatch may predict the response to thrombolysis. Due to the reliance on contrast agents in PWI, noninvasive alternatives remain an unmet need. Methods: We herein investigate the potentials of SWI as an alternative to PWI in defining ischemic penumbra and in predicting stroke outcome. A multimodal magnetic resonance imaging work-up which includes conventional magnetic resonance imaging sequences (T1WI, T2WI and FLAIR), DWI, PWI and SWI was performed. The Alberta Stroke Programme Early CT Score (ASPECTS) was used to evaluate the changes in DWI, SWI and PWI. Results: The mismatch of SWI-DWI was comparable with that of PWI-DWI (p>0.05). Furthermore, the grade of prominent vein and the cerebral blood volume in the ipsilateral brain tissue were positively correlated. Conclusions: SWI can be used as a noninvasive alternative to identify occlusive arteries and to evaluate the ischemic penumbra. The susceptibility vein sign may represent thrombosis in arteries whereby being helpful to identify responsible blood vessels in ischemic stroke.


2012 ◽  
Vol 27 (7) ◽  
pp. 822-830 ◽  
Author(s):  
Stéphane Lehéricy ◽  
Michael A. Sharman ◽  
Clarisse Longo Dos Santos ◽  
Raphaël Paquin ◽  
Cecile Gallea

US Neurology ◽  
2013 ◽  
Vol 09 (01) ◽  
pp. 8
Author(s):  
David A Ziegler ◽  
Suzanne Corkin ◽  
◽  

The pathophysiology of idiopathic Parkinson disease (PD) is traditionally characterized as substantia nigra degeneration, but careful examination of the widespread neuropathologic changes suggests individual differences in neuronal vulnerability. A major limitation to studies of disease progression in PD has been that conventional magnetic resonance imaging (MRI) techniques provide relatively poor contrast for the structures that are affected by the disease, and thus are not typically used in experimental or clinical studies. Here, we review the current state of structural MRI as applied to the analysis of the PD brain. We also describe a new multispectral MRI method that provides improved contrast for the substantia nigra and basal forebrain, which we recently used to show that these structures display different trajectories of volume loss early in the disease.


Sign in / Sign up

Export Citation Format

Share Document